Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Alfresa: Profits Plummet despite Large Increase in Sales
May 25, 2009
- Daiichi Sankyo: Net Loss of ¥335.8 Bil. Due to Ranbaxy Acquisition
May 25, 2009
- Ono: NHI Price Cuts, Competition with Generics Hit Business
May 25, 2009
- Astellas: Growth in Sales Halted below ¥1 Tril. Mark
May 25, 2009
- MTPC: Pharma Sales Up 2%; Remicade, Talion Drive Business
May 25, 2009
- Takeda: Record-High Sales of ¥1,538 Bil.
May 25, 2009
- DSP: New Products Make Up for Decreases in Sales of Amlodin
May 25, 2009
- Novartis to Make Everolimus Blockbuster in 5 Years: Mr D. Epstein
May 25, 2009
- REGULATORY NEWS IN BRIEF
May 25, 2009
- BUSINESS NEWS IN BRIEF
May 25, 2009
- FDA Approves ACTOplus met XR: Takeda
May 25, 2009
- 31 Generics of Cravit from 23 Firms Included in NHI Price List
May 25, 2009
- First Generics Listed for 13 APIs
May 25, 2009
- On-line Sale of Class 2 OTC Drugs to Be Permitted for 2 Years
May 18, 2009
- Torii: Sales Down 8.6% Due to Transfer of Stronger Neo Minophagen
May 18, 2009
- Taisho to Enter Market for Topical OTC NSAIDs with Diclotect
May 18, 2009
- Teijin Aims at ¥400 Bil. Sales for Drugs, Home Healthcare Business in 2020
May 18, 2009
- Novartis Launches Switch OTC Voltaren
May 18, 2009
- Merger Boosts Kyowa Kirin's Sales, Profits
May 18, 2009
- 18 APIs to Be Recommended as Switch OTC Drugs
May 18, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…